重点通报！油价四连跌！多地汽油重回“7元时代”

油价四连跌！多地汽油重回“7元时代”

北京6月13日讯 记者今天从国家发改委获悉，根据近期国际市场油价变化情况，按照现行成品油价格形成机制，自2024年6月13日24时起，国内汽、柴油价格（标准品）每吨分别下调190元、180元。折算升价后，国内92号汽油、95号汽油及0号柴油每升分别下调0.15元、0.16元、0.15元。

本次调价是今年国内成品油价格的第四次下调，也是年内首次降幅超过100元/吨。调整后，全国多数地区车柴油价格7.3-7.5元/升，92号汽油零售价在7.7-7.8元/升，多地汽油价格重回“7元时代”。

以油箱容量为50升的普通私家车计算，车主加满一箱92号汽油将少花7.5元左右；对满载50吨的大型物流运输车辆而言，平均每行驶一百公里，燃油费用减少6元左右。

国家发改委表示，本次调价遵循现行成品油价格形成机制，综合考虑了近期国际市场油价变化和国内成品油供需情况。当前，国际原油市场形势复杂多变，供需基本平衡，价格总体震荡运行。国内成品油库存总体充足，市场供应平稳。

发改委提醒广大消费者理性用油，安全行车，并加强对成品油市场价格监督检查，严厉打击违法违规行为，维护市场秩序。

（记者 王珊）

附：

• 本轮成品油调价周期内（4月29日至6月12日），参考原油品种均价为77.84美元/桶，变化率为-4.02%。
• 下一轮成品油调价周期将于2024年7月5日24时开启。

参考资料：

• 国家发改委关于汽柴油价格调整的通知 [移除了无效网址]
• 国内成品油价格年内“四连跌” 多地92号汽油重回“7元时代” [移除了无效网址]
• 年内第四次下调！多地汽油价格回归“7元时代”

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.